JP2024543931A - 抗ｓｏｓｔ抗体医薬組成物及びその使用 - Google Patents

抗ｓｏｓｔ抗体医薬組成物及びその使用 Download PDF

Info

Publication number
JP2024543931A
JP2024543931A JP2024531530A JP2024531530A JP2024543931A JP 2024543931 A JP2024543931 A JP 2024543931A JP 2024531530 A JP2024531530 A JP 2024531530A JP 2024531530 A JP2024531530 A JP 2024531530A JP 2024543931 A JP2024543931 A JP 2024543931A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
seq
sost
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531530A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543931A5 (enExample
Inventor
爽 ▲単▼
晨▲敏▼ 田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of JP2024543931A publication Critical patent/JP2024543931A/ja
Publication of JP2024543931A5 publication Critical patent/JP2024543931A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2024531530A 2021-11-30 2022-11-30 抗ｓｏｓｔ抗体医薬組成物及びその使用 Pending JP2024543931A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111462784.6 2021-11-30
CN202111462784 2021-11-30
PCT/CN2022/135247 WO2023098694A1 (zh) 2021-11-30 2022-11-30 一种抗sost抗体药物组合物及其用途

Publications (2)

Publication Number Publication Date
JP2024543931A true JP2024543931A (ja) 2024-11-26
JP2024543931A5 JP2024543931A5 (enExample) 2025-12-05

Family

ID=86611532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531530A Pending JP2024543931A (ja) 2021-11-30 2022-11-30 抗ｓｏｓｔ抗体医薬組成物及びその使用

Country Status (8)

Country Link
US (1) US20250011411A1 (enExample)
EP (1) EP4434517A4 (enExample)
JP (1) JP2024543931A (enExample)
CN (1) CN118175993A (enExample)
AU (1) AU2022401939A1 (enExample)
CA (1) CA3238868A1 (enExample)
TW (1) TW202330032A (enExample)
WO (1) WO2023098694A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
AR075715A1 (es) * 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
HK1200322A1 (en) * 2011-10-24 2015-08-07 Abbvie Inc. Immunobinders directed against sclerostin
SI3269735T1 (sl) 2015-03-13 2020-12-31 Jiangsu Hengrui Medicine Co. Ltd. Protitelo proti sklerostinu, antigen-vezavni fragment in medicinska uporaba le-tega
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN109952093B (zh) 2017-07-27 2022-02-08 江苏恒瑞医药股份有限公司 一种sost抗体药物组合物及其用途
EP4013786A1 (en) * 2019-08-12 2022-06-22 Amgen Inc. Anti-sclerostin antibody formulations

Also Published As

Publication number Publication date
AU2022401939A1 (en) 2024-05-30
TW202330032A (zh) 2023-08-01
CN118175993A (zh) 2024-06-11
WO2023098694A1 (zh) 2023-06-08
US20250011411A1 (en) 2025-01-09
EP4434517A1 (en) 2024-09-25
EP4434517A4 (en) 2025-06-25
CA3238868A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
US11612659B2 (en) Anti-CD40 antibody formulation delivery device
CN111315411B (zh) 高浓度抗c5抗体制剂
ES3008262T3 (en) High concentration antibody formulations
CN109952093B (zh) 一种sost抗体药物组合物及其用途
CN110732023A (zh) 一种her2抗体药物组合物及其用途
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
EP3131584B1 (en) Stable protein formulations comprising a molar excess of sorbitol
JP2018531980A (ja) 抗ｄ因子抗体製剤
TW201902518A (zh) 一種含c-Met抗體藥物偶聯物的醫藥組成物及其用途
JP7502286B2 (ja) 抗ｐｃｓｋ９抗体を含む安定製剤
US20250282882A1 (en) Pharmaceutical formulation comprising anti-ox40 monoclonal antibody
JP2024543931A (ja) 抗ｓｏｓｔ抗体医薬組成物及びその使用
KR102896927B1 (ko) 안정한 수성 항-tfpi 항체 제제
CN115227813A (zh) 一种含抗Abeta抗体的药物组合物
TW202541841A (zh) 用於治療ｃ１ｓ介導病症的包含抗體的醫藥組成物及其使用方法
HK40075201B (zh) 稳定的水性抗-tfpi抗体制剂
HK40009387A (en) Sost antibody pharmaceutical composition and uses thereof
HK40009387B (en) Sost antibody pharmaceutical composition and uses thereof
HK40023281A (en) Lyophilised and aqueous anti-cd40 antibody formulations
HK1202050B (en) Lyophilised and aqueous anti-cd40 antibody formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251119